company background image
CASI logo

CASI Pharmaceuticals NasdaqCM:CASI Stock Report

Last Price

US$6.14

Market Cap

US$88.3m

7D

10.5%

1Y

56.5%

Updated

29 Oct, 2024

Data

Company Financials +

CASI Pharmaceuticals, Inc.

NasdaqCM:CASI Stock Report

Market Cap: US$88.3m

CASI Stock Overview

A biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.

CASI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

CASI Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CASI Pharmaceuticals
Historical stock prices
Current Share PriceUS$6.14
52 Week HighUS$8.48
52 Week LowUS$2.05
Beta0.65
11 Month Change2.08%
3 Month Change-15.38%
1 Year Change56.51%
33 Year Change-45.22%
5 Year Change-80.65%
Change since IPO-99.65%

Recent News & Updates

Recent updates

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Sep 02
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

May 20
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

CASI Pharmaceuticals Q2 2022 Earnings Preview

Aug 11

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16
Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Shareholder Returns

CASIUS BiotechsUS Market
7D10.5%-0.2%-0.09%
1Y56.5%27.0%38.6%

Return vs Industry: CASI exceeded the US Biotechs industry which returned 28.6% over the past year.

Return vs Market: CASI exceeded the US Market which returned 39.5% over the past year.

Price Volatility

Is CASI's price volatile compared to industry and market?
CASI volatility
CASI Average Weekly Movement9.6%
Biotechs Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: CASI has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CASI's weekly volatility has decreased from 15% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991176Wei-Wu Hewww.casipharmaceuticals.com

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc

CASI Pharmaceuticals, Inc. Fundamentals Summary

How do CASI Pharmaceuticals's earnings and revenue compare to its market cap?
CASI fundamental statistics
Market capUS$88.33m
Earnings (TTM)-US$27.20m
Revenue (TTM)US$23.10m

4.0x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CASI income statement (TTM)
RevenueUS$23.10m
Cost of RevenueUS$9.98m
Gross ProfitUS$13.12m
Other ExpensesUS$40.33m
Earnings-US$27.20m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 14, 2024

Earnings per share (EPS)-1.81
Gross Margin56.81%
Net Profit Margin-117.77%
Debt/Equity Ratio204.7%

How did CASI perform over the long term?

See historical performance and comparison